Semenza GLHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4): 207-214

Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Trends in Pharmacological Sciences (Impact Factor: 11.54). 03/2012; 33(4):207-14. DOI: 10.1016/
Source: PubMed


Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In human cancers that are accessible for O(2) electrode measurements, intratumoral hypoxia is common and severe hypoxia is associated with increased risk of mortality. HIF activity in regions of intratumoral hypoxia mediates angiogenesis, epithelial-mesenchymal transition, stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy. A growing number of drugs have been identified that inhibit HIF activity by a variety of molecular mechanisms. Because many of these drugs are already FDA-approved for other indications, clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.

Full-text preview

Available from:
  • Source
    • "Our study aimed to analyze the effect of different pulsing protocols on siRNA electrotransfection efficiency and their effect on cell viability of cultured primary human myoblasts by using siRNA against HIF-1a mRNA. Silencing of HIF-1 was chosen as a model target for optimization of electroporation based siRNA delivery, since HIF-1 transcription factor has become one interesting molecular target to treat various diseases from ischemia to cancer, either by increasing or reducing HIF-1 activity [Ziello et al., 2007; Semenza, 2012]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction of genetic material into muscle tissue has been extensively researched, including isolation and in vitro expansion of primary myoblasts as a potential source of cells for skeletal and heart muscle tissue engineering applications. In this study, we optimized the electroporation protocol for introduction of short interfering ribonucleic acid (siRNA) against messenger RNA for Hypoxia Inducible Factor 1α (HIF-1α) into cultured primary human myoblasts. We established optimal pulsing protocol for siRNA electro transfection, and theoretically analyzed the effect of electric field and pulse duration on silencing efficiency and electrophoretic displacement of siRNA. Silencing of HIF-1α was determined with quantitative polymerase chain reaction and Western Blot. The most efficient silencing (71% knockdown) was achieved with 8 × 2 ms pulses, E = 0.6 kV/cm. Viability was determined immediately, 1 h and 48 h after electroporation. In general, there was a trade-off between efficient silencing and preserved viability. Electric field and pulse duration are crucial parameters for silencing, since both increase membrane permeabilization and electrophoretic transfer of siRNA. Short-term viability showed immediate toxicity of pulses due to membrane damage, while indirect effects on cell proliferation were observed after 48 h. Presented results are important for faster optimization of electroporation parameters for ex vivo electrotransfer of short RNA molecules into primary human myoblasts. Bioelectromagnetics. 2015;9999:XX-XX. © 2015 Wiley Periodicals, Inc.
    Full-text · Article · Sep 2015 · Bioelectromagnetics
  • Source
    • "During hypoxia, or in case of VHL-gene mutations, HIFa subunits accumulates as a result of pVHL inability to determine their destruction, leading to stably up-regulation of hypoxia-response elements (HREs) such as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF), and the glucose transporter, GLUT1 [12]. HIF transcriptional activity, especially HIF2a activity [13], mediates angiogenesis, epithelial– mesenchymal transition (EMT), stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy in kidney cancer [14]. While HIF-1a and HIF-2a demonstrate overlapping effects on angiogenesis and ECM remodeling, they differ in controlling cell metabolism, proliferation, and oncogene activation in human ccRCCs [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR pathways). We analyzed the key metabolic abnormalities underlying RCC carcinogenesis, highlighting those altered pathways that may represent potential targets for the development of more effective therapeutic strategies. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Full-text · Article · Jul 2015 · Cancer Treatment Reviews
  • Source
    • "This mechanism describes a natural selection of primary tumor cells with more radioresistant properties which have the ability to survive in harsh microenvironmental conditions induced by radiotherapy, such as hypoxia. As hypoxia resistance is a well-known property of metastatic cells [31] [32] [33], the induced radioresistance might go hand in hand with increased metastatic potential of surviving tumor cells. The hypothesis that radioresistance (be it intrinsic or induced) and metastatic potential might be related, is confirmed by the results of this study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neoadjuvant chemoradiotherapy is used prior to surgery in curative treatment of esophageal cancer (EC). We evaluated the in-field control of this multimodal treatment by extraction of radiation dose parameters and determination of the spatial relation between tumor recurrence location(s) and radiation target volume (RTV). Treatment consisted of neoadjuvant chemotherapy (5-FU and cisplatin) and radiotherapy (36Gy) followed by Ivor-Lewis esophagectomy. For patients with locoregional recurrence(s), image fusion was performed between radiotherapy planning CT and follow-up CT(s). A region-of-interest was contoured on the planning CT around each locoregional recurrence. Mean and maximum radiation doses were then extracted to classify recurrences as out-of-field, marginal or in-field. Eighty patients were included. The median follow-up duration was 19months. Fifteen of 95 locoregional recurrences were detected in the RTV. These in-field relapses occurred in only 6 patients (7.8%) on 12 different anatomical locations. None of the patients with in-field failure had a pCR and all had concurrent distant failure on multiple anatomical sites. Neoadjuvant chemoradiotherapy followed by Ivor-Lewis esophagectomy yields excellent in-field control, as only a clear minority (7.8%) of patients developed a relapse in the RTV. In-field recurrence is associated with widespread tumor dissemination and poor pathological response to neoadjuvant treatment. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Full-text · Article · Mar 2015 · Radiotherapy and Oncology
Show more